search
Back to results

Magnetic Imaging for Diagnostic of Amyotrophic Lateral Sclerosis (MIDALS)

Primary Purpose

Amyotrophic Lateral Sclerosis With Dementia

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Whole Body MRI and ENMG
Sponsored by
University Hospital, Toulouse
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Amyotrophic Lateral Sclerosis With Dementia focused on measuring Amyotrophic, Sclerosis

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Consent form signed by the patient
  • Patients suspected ALS defined according Awaji Shima criteria (possible, probable, defined)
  • Clinical assessment of upper motor neuron involvement
  • Electrophysiologic assessment of lower motor neuron involvement

Exclusion Criteria:

  • inability to give informed consent
  • a contraindication to MRI
  • respiratory failure impairing ability to lie flat in the scanner.
  • Patient placed under judicial protection or under another protective regime,
  • Females who are pregnant

Sites / Locations

  • Pascal CINTASRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

ENMG and muscle analyses on whole body muscles MRI.

Arm Description

Diffusion of active and chronic muscle denervation will be assessed on ENMG and whole body muscle MRI. The diagnostic category will be determined by revised El Escorial criteria and Awaji criteria

Outcomes

Primary Outcome Measures

Diagnostic certainty 1.ENMG according to El Escorial revised criteria using ENMG alone, MRI alone and ENMG+MRI to define denervation diffusion
number of patients classified as possible, probable or certain according to El Escorial criteria using ENMG alone, IMR alone and ENMR+MRI

Secondary Outcome Measures

Define precise topographic and characteristic of muscle involvement in ALS by MRI
number of patients with concordance between ENMG and MRI for the detection of denervation

Full Information

First Posted
March 26, 2021
Last Updated
July 10, 2023
Sponsor
University Hospital, Toulouse
search

1. Study Identification

Unique Protocol Identification Number
NCT04868994
Brief Title
Magnetic Imaging for Diagnostic of Amyotrophic Lateral Sclerosis
Acronym
MIDALS
Official Title
Contribution of Whole Body Muscle MRI for Early Diagnosis of Amyotrophic Lateral Sclerosis.
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 1, 2021 (Actual)
Primary Completion Date
December 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Toulouse

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Nearly 60% of Amyotrophic Lateral Sclerosis (ALS) patients have a low level of diagnostic certainty (possible, probable) at the time of diagnosis. In the absence of biomarkers, this diagnosis is based, among other things, on the demonstration of the diffusion of signs of denervation by electroneuromyography (ENMG). The objective of this study is to improve the earliness and the level of diagnostic certainty by better demonstrating the diffusion of the denervation process by whole body muscular MRI.
Detailed Description
The objective of this study is to show that the combination of ENMG and whole body muscle MRI (WB-MRI) can increase the diagnosis of definite ALS at the onset of the disease For 50 consecutive patients with suspected ALS, the present study will prospectively perform needle electromyography (EMG) and muscle analyses on whole body MRI. The diagnostic category will be determined by revised El Escorial criteria and Awaji criteria. On whole body MRI acquisition, for 83 muscles, will be explored fatty infiltration and atrophy on fat images (chronic denervation) and muscle edema on water images (acute denervation). EMG studies will be performed in at least 10 muscles (tongue, biceps brachii, first dorsalis interosseous, T10 paraspinalis, vastus lateralis, and tibialis anterior). Diagnostic classification according EMG and/ or MRI abnormalities in bulbar and the 3 spinal regions will be compared independently.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Amyotrophic Lateral Sclerosis With Dementia
Keywords
Amyotrophic, Sclerosis

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ENMG and muscle analyses on whole body muscles MRI.
Arm Type
Experimental
Arm Description
Diffusion of active and chronic muscle denervation will be assessed on ENMG and whole body muscle MRI. The diagnostic category will be determined by revised El Escorial criteria and Awaji criteria
Intervention Type
Diagnostic Test
Intervention Name(s)
Whole Body MRI and ENMG
Intervention Description
Whole body muscle MRI lasting 30 to 45 min without injection of contrast medium an ENMG
Primary Outcome Measure Information:
Title
Diagnostic certainty 1.ENMG according to El Escorial revised criteria using ENMG alone, MRI alone and ENMG+MRI to define denervation diffusion
Description
number of patients classified as possible, probable or certain according to El Escorial criteria using ENMG alone, IMR alone and ENMR+MRI
Time Frame
1 month
Secondary Outcome Measure Information:
Title
Define precise topographic and characteristic of muscle involvement in ALS by MRI
Description
number of patients with concordance between ENMG and MRI for the detection of denervation
Time Frame
1 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Consent form signed by the patient Patients suspected ALS defined according Awaji Shima criteria (possible, probable, defined) Clinical assessment of upper motor neuron involvement Electrophysiologic assessment of lower motor neuron involvement Exclusion Criteria: inability to give informed consent a contraindication to MRI respiratory failure impairing ability to lie flat in the scanner. Patient placed under judicial protection or under another protective regime, Females who are pregnant
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Pascal CINTAS, MD PHD
Phone
05 61 77 94 40
Email
cintas.p@chu-toulouse.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Anne Cecile Coville
Phone
(05345) 58700
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pascal CINTAS, MD
Organizational Affiliation
University Hospital, Toulouse
Official's Role
Principal Investigator
Facility Information:
Facility Name
Pascal CINTAS
City
Toulouse
ZIP/Postal Code
31000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pascal CINTAS, MD PHD
Phone
0561779440
Email
cintas.p@chu-toulouse.fr
First Name & Middle Initial & Last Name & Degree
Anne Cecile Coville
Phone
0534558700

12. IPD Sharing Statement

Learn more about this trial

Magnetic Imaging for Diagnostic of Amyotrophic Lateral Sclerosis

We'll reach out to this number within 24 hrs